Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid tumors; MCLA-145, which is in phase 1 clinical trials for the treatment of solid tumors; MCLA-129, which is in phase 1/2 clinical trials for the treatment of patients with advanced non-small cell lung cancer and other solid tumors; and ONO-4685 that is Phase 1 clinical trial to treat relapsed/refractory T cell lymphoma. In addition, it has collaboration agreement with Betta Pharmaceuticals Co. Ltd for the research and development of stage bispecific antibody candidates include MCLA-129; and collaboration with Incyte Corporation for the development of MCLA-145. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Earnings for Merus N.V. (MRUS)
Earnings in 2023 (TTM): $-151,747,000
According to Merus N.V.'s latest financial reports the company's current earnings (TTM) are $-151,747,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Merus N.V.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-151,747,000 | $-154,939,000 |
| 2022 | $-130,235,000 | $-131,194,000 |
| 2021 | $-66,577,000 | $-66,816,000 |
| 2020 | $-85,010,000 | $-85,513,000 |
| 2019 | $-54,957,000 | $-55,151,000 |
| 2018 | $-27,354,152 | $-27,761,382 |
| 2017 | $-87,386,328 | $-87,685,054 |
| 2016 | $-49,669,766 | $-49,669,766 |
| 2015 | $-25,347,124 | $-25,347,124 |
| 2014 | $-21,169,561 | $-21,169,561 |
| 2013 | $-13,681,681 | $-13,681,681 |